Annual Report 2012.pdf - Karo Bio

acCounts
Consolidated income statements and income
statements for the Parent Company
GROUP
PARENT COMPANY
KSEK Note 2012 2011 2010 2012 2011
Net sales 1 33,173 - - 33,173 -
Operating expenses 2–5
Administrative expenses –25,116 –40,797 –32,869 –25,116 –40,797
R&D expenses –107,857 –189,321 –129,382 –108,207 –189,321
Other operating income and expenses 6 51 –1,041 412 51 –1,041
–132,922 –231,159 –161,839 –133,272 –231,159
Operating profit/loss –99,749 –231,159 –161,839 –100,099 –231,159
Income from financial investments
Interest income and other similar income 7 1,510 5,921 802 1,510 5,921
Interest expenses and other similar expenses 8 –15 –1,388 –2,500 –3 –1,374
1,495 4,533 –1,698 1,507 4,547
Profit/loss after financial items –98,254 –226,626 –163,537 –98,592 –226,612
Tax 9 - - - - -
PROFIT/LOSS FOR THE YEAR 10 –98,254 –226,626 –163,537 –98,592 –226,612
Earnings per share (SEK) 11
– based on weighted average number of
shares outstanding –0.25 –0.59 –0.67
– based on weighted average number of
shares fully diluted 1) –0.25 –0.59 –0.67
1)
The last day for redemption for the warrants that were issued in the latest program was in April 2011.
No dilutive effect from warrants outstanding is therefore taken into account.
Consolidated statement of comprehensive
income and comprehensive income for the
Parent Company
GROUP
PARENT COMPANY
KSEK Note 2012 2011 2010 2012 2011
Profit/loss for the period –98,254 –226,626 –163,537 –98,592 –226,612
Othet comprehensive income for the year, net of tax - - - - -
TOTAL COMPREHENSIVE PROFIT/LOSS
FOR THE PERIOD –98,254 –226,626 –163,537 –98,592 –226,612
Total comprehensive profit/loss attributable to:
Shareholders of the parent company –98,254 –226,626 –163,537 –98,592 –226,612
18 KARO BIO Annual Report 2012